Abstract
Change in diet, life style and increased life expectancy has led to the dramatic escalation in old age related complication like cognitive decline leading to dementia. Cardiovascular diseases (CVD) are huge risk factors for dementia, including Alzheimer disease (AD). Hypertension is very well known to cause cognitive impairment. Control of CVD could provide protection against dementia. Earlier, in the mouse model of AD, reserpine, an antihypertensive and antipsychotic drug could elicit improvement in the working memory in AD model mice and enhance the same in normal mice. Hence, Cognitive protection in the patients on chronic antihypertensive drug which contains reserpine was evaluated. Cognition in a cohort (in the South Indian rural population) of hypertensive patients (majority age group – 50-70 years) who have been chronically treated with a combinatorial drug, (adelphane/adelphane esidrex-Novaritis, Switzerland) consisting of reserpine and hydrazine for years was compared with controls without hypertension. The cohorts were age, sex, socio-economic, education background matched. Cognition was scored using the Tamil version of: Addenbrooke’s Cognitive Examination-III (T-ACEIII) and Tamil-Montreal Cognitive Assessment (T-MoCA) scales. The composite T-ACEIII score of control and treated groups were 53.6 and 53.2, respectively. T-MoCA scores (Control-15.1 and Treated-14.7) did not show much alteration. Further, the mean scores of the control and treated groups’ individual components of cognition in ACE, namely, Attention, Memory, Fluency, Language and visuospatial – cognitive skills also did not reveal significant difference. Thus, controlling blood pressure or hypertension with chronic antihypertensive medication like adelphane/adelphane esirdex (reserpine containing drugs) has retained normal cognition in both genders.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
There was no financial support provided for this study
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All the data has been consolidated and presented. This data was collected more than 3 years back. So, they may not be available.
